HomeCompareHOPHF vs KMB

HOPHF vs KMB: Dividend Comparison 2026

HOPHF yields 85.84% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HOPHF wins by $2.10M in total portfolio value
10 years
HOPHF
HOPHF
● Live price
85.84%
Share price
$2.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.14M
Annual income
$651,617.80
Full HOPHF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — HOPHF vs KMB

📍 HOPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOPHFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOPHF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOPHF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOPHF
Annual income on $10K today (after 15% tax)
$7,296.14/yr
After 10yr DRIP, annual income (after tax)
$553,875.13/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, HOPHF beats the other by $549,445.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOPHF + KMB for your $10,000?

HOPHF: 50%KMB: 50%
100% KMB50/50100% HOPHF
Portfolio after 10yr
$1.10M
Annual income
$328,414.56/yr
Blended yield
29.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

HOPHF
No analyst data
Altman Z
-26.6
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOPHF buys
0
KMB buys
0
No recent congressional trades found for HOPHF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOPHFKMB
Forward yield85.84%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$2.14M$45.9K
Annual income after 10y$651,617.80$5,211.33
Total dividends collected$1.88M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: HOPHF vs KMB ($10,000, DRIP)

YearHOPHF PortfolioHOPHF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$19,284$8,583.69$11,314$613.68+$8.0KHOPHF
2$36,103$15,469.65$12,865$759.19+$23.2KHOPHF
3$65,698$27,067.75$14,709$943.96+$51.0KHOPHF
4$116,331$46,033.72$16,919$1,180.17+$99.4KHOPHF
5$200,653$76,178.70$19,588$1,484.33+$181.1KHOPHF
6$337,499$122,800.47$22,838$1,879.06+$314.7KHOPHF
7$554,162$193,038.35$26,832$2,395.60+$527.3KHOPHF
8$889,180$296,226.83$31,788$3,077.63+$857.4KHOPHF
9$1,395,638$444,215.43$38,000$3,986.82+$1.36MHOPHF
10$2,144,951$651,617.80$45,872$5,211.33+$2.10MHOPHF

HOPHF vs KMB: Complete Analysis 2026

HOPHFStock

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Full HOPHF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this HOPHF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOPHF vs SCHDHOPHF vs JEPIHOPHF vs OHOPHF vs KOHOPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.